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OBJECTIVE: The aim of the study was to investigate
gender differences in persistence with antihypertensive
drugs (AHT). METHODS: Data for this study were
obtained from the PHARMO system including pharmacy
records and hospitalisations in the Netherlands (n =
950,000). Patients between 1997–2001 who newly
received monotherapy of AHTs were selected. One-year
persistence was deﬁned as the percentage of patients using
AHTs at least 270 days and receiving AHT in 3 months
after the 1-year follow-up period. Persistence was pre-
sented as 1-year persistence (95% CI). Odds ratios (OR)
were calculated with logistic regression and adjusted for
age, use of antidiabetics and lipid lowering drugs, and
prior cardiovascular hospitalizations. RESULTS: In the
period 1997–2001, 17,113 patients newly received at
least one AHT prescription with a follow-up >15 months.
Of these patients, random samples of 500 patients per
drug class were drawn. Persistence was highest in
angiotensin II receptor blockers (ARBs) (62.1%), pro-
gressively lower in ACE-inhibitors (60.2%), betablockers
(35.5%), calcium channel blockers (34.7%), and diuret-
ics (33.0%), resulting in the highest OR of 3.3 [95% CI:
2.5–4.4] for ARBs compared to diuretics. The persistence
of AHT use in women is substantially lower than in men
(40.4% versus 50.3%, OR 0.7 [95% CI: 0.6–0.8]). CON-
CLUSIONS: These results demonstrate marked differ-
ences in persistence between AHT classes, with the
highest persistence for ARBs and lowest for diuretics.
Women were less persistent with their AHT compared to
men. This low persistence leads to suboptimal treatment
with substantial consequences. Especially in women,
more improvement can be gained to improve their car-
diovascular outcome.
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OBJECTIVES: In a previous study, we have identiﬁed side
effects and lack of drug insurance coverage as the deter-
minants of discontinuation in a group of patients newly
prescribed antihypertensive medications. The current
study aimed at identifying the determinants of non adher-
ence to medication among those who had not discontin-
ued. METHODS: We conducted a prospective cohort
study in which individuals prescribed a new antihyper-
tensive monotherapy were identiﬁed through a network
of 173 pharmacies. We interviewed participants by tele-
phone three times over a 3-month period. At the end of
this period, those individuals which reported still taking
the medication initially prescribed, were included in the
analysis. Self-reported non adherence was measured at
three month using the Morisky’s 4-item questionnaire.
Those answering yes to any one of the 4 questions were
deemed to be non adherent. We analyzed data using a
multivariable logistic regression model. RESULTS: Of
509 eligible participants, 118 (23.2%) reported non
adherence to their drug treatment. Non adherence was
signiﬁcantly associated with the use of angiotensine con-
verting enzyme inhibitors (Adjusted Odds Ratio (AOR) =
3.0; 95% Conﬁdence Interval (CI) 1.2–7.9) as compared
to angiotensin II antagonist losartan, and the belief that
hypertension is not a risk factor for cardiovascular dis-
eases (AOR = 2.0; 95% CI 1.2–3.3). On the other hand,
non adherence was inversely associated with the use of
more than 4 pills of medication a day (AOR = 0.3; 95%
CI 0.2–0.6). CONCLUSIONS: Our ﬁndings suggest that
determinants of non adherence are not the same as those
for discontinuation. They also suggest that adherence to
drug treatment could be improved by a proper selection
of medication, and by attempts to correct wrong percep-
tions patients may have about hypertension. Our ﬁnding
that taking more than four pills was associated with
better adherence is concordant with data recently pub-
lished by others.
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OBJECTIVES: To compare the discontinuation rates due
to poor tolerability in patients with overactive bladder
treated with either once daily dosed extended release
(XL), or twice or greater daily dosed, immediate release
(IR) oxybutynin. METHODS: We used the real-world
longitudinal data (1995–2002) from IMS Mediplus UK
to identify all patients new to therapy initiated on either
oxybutynin IR or XL. The ﬁrst script deﬁned the patients
study cohort and the date of that script was the study
index date from which monitoring outcomes followed.
These scripts were linked to reason to stop therapy,
including poor tolerability. The start-date-match ap-
proach was used to adjust for the later market entrance
of oxybutynin XL. We used c2 test to evaluate the statis-
tical signiﬁcance in the difference of discontinuation rates
between both groups. RESULTS: We identiﬁed 147
patients initiated on oxybutynin XL and 216 patients on
oxybutynin IR, with an average daily dose of 10.0mg and
8.9mg respectively. Patient demographics were compara-
ble. In the oxybutynin XL group, 29 patients (19.7%)
had a record for stopping therapy compared to 129
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patients (67.6%) in the oxybutynin IR group. Of those
with a stopping therapy record, discontinuation rates due
to poor tolerability were 3.4% versus 14.4% (p < 0.01)
for the XL and IR groups, respectively. The most frequent
recorded reason for the oxybutynin IR group was change
in formulation or titration, 20.8% compared to 4.8% for
the XL group, followed by poor tolerability, and lack of
effect (8.3% for the IR group compared to 3.4% for the
XL group). Of the 216 oxybutynin IR patients, 120 sub-
sequently switched to oxybutynin XL. CONCLUSIONS:
The improved tolerability of oxybutynin XL compared to
oxybutynin IR demonstrated in randomized clinical trials
is reﬂected in the UK real-world clinical practice setting:
patients on oxybutynin XL have signiﬁcantly lower dis-
continuation rates.
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OBJECTIVES: To assess long-term persistence with 
statin use in the general population and to identify 
determinants of failure to persist with these drugs.
METHODS: Data were obtained from the PHARMO
database including linked pharmacy records and hospital
discharge records of 865,000 subjects in The Nether-
lands. In the period 1998–2001, all new users of statins,
deﬁned as patients not receiving any statin for at least 
2 years before the ﬁrst dispensing of a statin, were
extracted. Episodes of statin use were constructed for
each patient. In case of interruptions between two pre-
scriptions of <45 days, the episode was considered 
uninterrupted. The effects of several determinants on per-
sistence in the ﬁrst episode were assessed using Cox pro-
portional hazard analysis RESULTS: A total of 8335
starters with statins were selected. Persistence with use at
one year was 63.7% (95% CI 62.7%–64.8%) for all
statins, and decreased to 48.5% (95% CI 47.4%–49.6%)
at two years. Determinants predicting failure to persist
included older age (RR = 0.82; 95% CI 0.74–0.91 for
those >65 years compared to those <45 years), a history
of antihypertensive drug use (RR = 0.91; 95% CI
0.85–0.98), psychotropic drug use (RR = 1.13; 95% CI
1.06–1.20), or hospitalisation for ischaemic heart disease
(RR = 0.78; 95% CI 0.70–0.88). Compared to starters
with simvastatin, the risk of discontinuation was lower
for atorvastatin (RR = 0.90; 95% CI 0.83–0.96), similar
for pravastatin (RR = 0.99; 95% CI 0.91–1.08), and
higher for ﬂuvastatin (RR = 1.27; 95% CI 1.12–1.39).
CONCLUSIONS: Persistence with statin use declined
over time, and is low compared to trial settings. Hence,
the number of patients needed to treat to prevent one
coronary event as observed in these trials drastically
increases in daily medical practice.
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OBJECTIVES: The purpose of this pharmacoeconomic
analysis was to compare the cost effectiveness of r-hCG
(Ovidrel®) and u-hCG (Novarel®) for ART in the USA.
Customized mathematical modeling of the economics of
infertility treatment was used to overcome the limitations
of clinical studies. METHODS: The mathematical model
incorporated a Markov varying decision framework and
Monte-Carlo computerized multiple simulations. Statisti-
cal representations of recurrent events over time were
incorporated into a decision analysis involving fresh and
frozen cycles in any sequence (after the ﬁrst fresh embryo
transfer cycle) over three successive ART attempts. Dif-
ferential information used in the model came from a 
speciﬁc meta-analysis of three published clinical trials.
Outcomes were expressed in terms of percentage of live
births and percentage of singletons. Transition probabil-
ities were derived from the medical literature and statis-
tical reports. Information concerning ART and antenatal
costs came from statistical surveys. The speciﬁc distribu-
tion curve of antenatal costs in the USA was incorporated
into the model according to a gamma distribution. The
distribution of transition probabilities was analyzed
according to a normal distribution. Costs and cost-
effectiveness were calculated from both the societal 
perspective and the managed care organization (MCO)
perspective. RESULTS: This study involved 5,000 Monte-
Carlo treatment simulations on a Markov cohort of
100,000 patients. The live birth rate and the rate of sin-
gleton births were signiﬁcantly higher with r-hCG com-
pared with u-hCG (25.97% vs. 23.58% for live births 
p < 0.001 and 21.25% vs. 16% for singleton births p <
0.001). From the societal perspective, the cost per live
birth (US $72,671 vs. US $87,376) and per singleton birth
(US $89,005 vs. US $130,007) was signiﬁcantly lower
with r-hCG compared with u-hCG (p < 0.001 for both
cases). Costs were also signiﬁcantly lower with r-hCG
from the MCO perspective: US $49,444 vs. US $59,741
per live birth (p < 0.001) and US $60,562 vs. US $88,894
per singleton birth (p < 0.001). CONCLUSION: r-hCG
is more cost-effective than u-hCG.
